Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Suprefact (buserelin acetate)
i
Other names:
Hoe 766, S-746766
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sanofi
Drug class:
GnRH agonist
Related drugs:
‹
leuprolide acetate (14)
triptorelin (9)
goserelin acetate (7)
histrelin acetate (5)
leuprolide 6-month depot (1)
leuprorelin depot (1)
leuprolide acetate for depot suspension (1)
leuprolide acetate (14)
triptorelin (9)
goserelin acetate (7)
histrelin acetate (5)
leuprolide 6-month depot (1)
leuprorelin depot (1)
leuprolide acetate for depot suspension (1)
›
Associations
News
Trials
Filter by
Latest
almost3years
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov)
P3, N=2478, Recruiting, NRG Oncology | Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033
almost 3 years ago
Enrollment open • Trial completion date
|
CD4 (CD4 Molecule)
|
bicalutamide • Erleada (apalutamide) • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login